Filing Signals

Source: SEC EDGAR Compiled 2026-11-13 17:17 UTC 23 automated checks passing

← All events

GoodRx Holdings, Inc.

CIK 1809519 GDRX·Services · All EDGAR filings ↗

Progression

  1. Auditor change 8-K
  2. Finance chief departure 8-K +9d
  3. Restatement 8-K +220d
  4. Late filing NT 10-Q +8d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing high Filing comparison

GoodRx Holdings, Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed 4 days before the statutory due date.

(the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 2, 2026, the Company has concluded that its condensed consolidated financial statements for the fiscal quarter and year-to-date periods ended March 31, 2026 and June 30, 2026 (collectively, the “Affected Periods”) should no longer be relied upon. Specifically, in connection with an Audit and Risk Committee review of the Company’s revenue recognition for certain…
Evidence
Anticipates significant change
No
Days past due date
-4
Other periodic reports filed
Yes
Routine
No
Severity
high
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 2, 2026, the Company has concluded that its condensed consolidated financial statements for the fiscal quarter and year-to-date periods ended March 31, 2026 and June 30, 2026 (collectively, the “Affected Periods”) should no longer be relied upon. Specifically, in connection with an Audit and Risk Committee review of the Company’s revenue recognition for certain…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Restatement SEC item code

GoodRx Holdings, Inc. said previously issued financial statements should no longer be relied upon

Item 4.02(a) — management or the board reached the conclusion

Evidence
Item code
4.02
Item title
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Limb
a
Limb basis
filing says management or the board concluded
Limb label
Item 4.02(a) — management or the board reached the conclusion
Severity
normal
Source
SEC 8-K item code
Why
The company told investors that previously issued financial statements should no longer be relied upon.

Source filing ↗

Finance chief departure Filing comparison

GoodRx Holdings, Inc.'s Chief Accounting Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Accounting Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Auditor change SEC item code

GoodRx Holdings, Inc. reported a change in its independent accounting firm

The company dismissed the auditor. PwC → not stated No disagreements disclosed.

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Disagreements disclosed
No
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
PwC
Predecessor tier
big_four
Severity
normal
Source
SEC 8-K item code
Why
The company's independent registered accounting firm changed.

Source filing ↗